Mestranol-Induced Reversible Lysosomal Stress in Zebrafish Microglia

Study Background and Research Question

Microglia, the resident immune cells of the central nervous system (CNS), are vital for maintaining brain homeostasis, mediating synaptic pruning, and removing apoptotic cells and debris through phagocytosis followed by lysosomal degradation. Disruption of microglial lysosomal function is increasingly implicated in neurodevelopmental and neurodegenerative conditions, as well as in lysosomal storage diseases (LSDs), where impaired degradation leads to the accumulation of undegraded substrates and cellular dysfunction. While genetic models of LSDs have provided key mechanistic insights, the capacity for environmental or pharmacological exposures to induce similar lysosomal stress states in microglia remains poorly understood.

Environmental estrogens such as mestranol, a synthetic estrogenic compound, are recognized neurotoxicants, but their effects on intracellular homeostasis in microglia in vivo are not well characterized. The primary research question of this study is whether mestranol can induce an acquired, reversible lysosomal storage–like state in microglia, and if so, what are the functional and molecular hallmarks of this state?

Key Innovation from the Reference Study

The main innovation of this study lies in establishing a live, pharmacologically controlled zebrafish model to investigate reversible lysosomal dysfunction in microglia. Unlike traditional genetic models for LSDs, this approach demonstrates that transient exposure to mestranol can induce a lysosomal storage–like phenotype in vivo, which is fully reversible upon drug withdrawal. This model allows for dynamic interrogation of environmental impacts on microglial lysosomal health and provides a tractable system for exploring neuroimmunotoxicity and potential intervention strategies.

Methods and Experimental Design Insights

The researchers utilized zebrafish larvae as a live imaging model, leveraging their optical transparency and genetic tractability. Microglial morphology and function were assessed through a combination of fluorescent reporter lines, neutral red staining (to visualize acidic lysosomal compartments), and flow cytometry-based cell sorting for transcriptomic profiling. The team exposed zebrafish larvae to mestranol and evaluated microglial responses with and without subsequent drug withdrawal to assess reversibility.

Functional assays included phagocytosis of apoptotic neurons and bacterial particles, alongside lysosomal digestion efficiency measurements. Acidic vesicle expansion and dispersal were assessed using live imaging and staining, while immune and lysosomal gene expression profiles were obtained via RNA sequencing of flow-sorted microglia/macrophages. Rescue experiments involved overexpression of TFEC, a MIT/TFE family transcription factor, to probe the mechanistic underpinnings of mestranol-induced changes.

Protocol Parameters

• Mestranol exposure: Acute and reversible dosing in zebrafish larvae; precise concentrations and exposure windows tailored for developmental stage and imaging compatibility.
• Neutral red staining: Applied post-exposure to visualize lysosomal compartments; interpret loss of staining as lysosomal dysfunction.
• Phagocytosis assessment: Quantify uptake of labeled apoptotic neurons or bacterial particles; pair with degradation assays to distinguish between cargo uptake and digestion.
• Transcriptomic profiling: Flow-sort microglia/macrophage populations for RNA sequencing; focus on lysosomal, phagosomal, and immune gene networks.
• Rescue experiment: TFEC overexpression via genetic or pharmacological means to dissect transcriptional regulation.

Core Findings and Why They Matter

Exposure to mestranol caused pronounced hypertrophy of microglia and a marked reduction in neutral red staining, indicating loss of lysosomal function, as shown in the study. Importantly, mestranol did not affect microglial numbers nor induce neuronal apoptosis, suggesting that the observed phenotype was not secondary to cell death but rather represented a direct impairment of lysosomal degradation. Functional analyses confirmed that while mestranol-treated microglia retained the ability to phagocytose cargo, they were unable to efficiently digest internalized material, resulting in intracellular accumulation. This dissociation between phagocytosis and degradation is a key hallmark of lysosomal storage–like states.

Expansion and cytoplasmic dispersal of acidic vesicles and protease-associated compartments were observed, yet degradative efficiency remained impaired, highlighting that formation of acidic phagolysosomes does not guarantee functional digestion. Transcriptomic profiling revealed that mestranol exposure coordinately downregulated lysosomal–phagosomal and immune gene networks, including critical transcriptional regulators such as TFEB and TFEC, alongside immune master regulators (SPI1, IRFs, BATF, MAFB, RUNX3). Overexpression of TFEC partially rescued the lysosomal and morphological defects, pointing to both TFEC-dependent and independent mechanisms in the regulation of microglial lysosomal stress.

Crucially, all mestranol-induced changes were reversible upon withdrawal of the compound, demonstrating the dynamic plasticity of microglial lysosomal function in response to environmental estrogen exposure. This reversibility distinguishes the model from classical genetic LSDs and provides a unique platform for exploring therapeutic interventions and recovery mechanisms.

Comparison with Existing Internal Articles

The findings in this study are supported and further contextualized by internal literature. For instance, one internal summary emphasizes that mestranol-induced lysosomal stress occurs without increased apoptosis, reinforcing the dissociation between microglial viability and lysosomal function. Similarly, the thought-leadership article on Annexin V-Cy5 platforms discusses how sensitive apoptosis assays, such as those using Annexin V-Cy5, can be leveraged to verify that pharmacologically induced lysosomal stress does not confound apoptosis detection in neuroimmunotoxicity models. The Annexin V-Cy5 Apoptosis Kit workflow review further explores the intersection of live cell apoptosis detection with models of reversible microglial dysfunction, providing protocol optimization insights for researchers utilizing similar zebrafish or neurodegenerative disease models.

Limitations and Transferability

While this zebrafish model offers several advantages—transparency, genetic tractability, and rapid imaging—it also presents limitations. The relevance of acute mestranol-induced lysosomal stress to chronic or developmental exposures in mammals remains to be established. Zebrafish microglia, while conserved in many aspects, may differ in some regulatory pathways compared to mammalian systems. Additionally, the partial rescue by TFEC overexpression suggests that other, as-yet-unidentified factors mediate mestranol’s effects on lysosomal function. The use of environmental estrogens as models for acquired lysosomal stress should be interpreted with caution when extrapolating to genetic or chronic disease contexts.

Why this cross-domain matters, maturity, and limitations

This research bridges environmental toxicology and neuroimmunology by showing that environmental estrogens can transiently modulate microglial lysosomal health in vivo. The model enables rapid, reversible induction of lysosomal stress states, facilitating screening of genetic and pharmacological modifiers relevant to both environmental exposures and lysosomal storage disorders. However, cross-domain extrapolation to mammalian or human neurodegeneration models requires further validation, and findings should be integrated with complementary approaches such as rodent models and human cell systems.

Research Support Resources

For researchers aiming to distinguish between lysosomal dysfunction and apoptosis in microglial or neurodegenerative disease models, reliable detection of early apoptotic events is critical. The Annexin V-Cy5 Apoptosis Kit (SKU K2005) from APExBIO offers a streamlined, sensitive workflow for detecting phosphatidylserine exposure—a hallmark of early apoptosis—via flow cytometry or fluorescence microscopy. This kit can complement studies of microglial resilience and lysosomal stress, ensuring accurate assessment of cell death and supporting robust interpretation of neuroimmunotoxicity findings. For protocol guidance and cross-validation strategies in similar zebrafish or mammalian models, see the referenced internal articles above.